Brokerages Set Kalaris Therapeutics Inc. (NASDAQ:KLRS) Target Price at $18.75

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $18.75.

Several research analysts have issued reports on the company. Morgan Stanley started coverage on Kalaris Therapeutics in a research report on Thursday, April 16th. They set an “overweight” rating and a $14.00 target price for the company. Wall Street Zen lowered Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Wedbush initiated coverage on Kalaris Therapeutics in a report on Thursday, May 14th. They set an “outperform” rating and a $17.00 price objective for the company. Citizens Jmp cut their price objective on Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, Weiss Ratings lowered Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th.

Kalaris Therapeutics Price Performance

Kalaris Therapeutics stock opened at $3.94 on Thursday. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $11.88. The firm’s 50 day moving average price is $4.25 and its 200-day moving average price is $6.19. The stock has a market cap of $93.73 million, a P/E ratio of -1.95 and a beta of 0.20.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.02. As a group, equities analysts expect that Kalaris Therapeutics will post -2 EPS for the current year.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju acquired 244,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $4.83 per share, for a total transaction of $1,179,969.00. Following the acquisition, the director directly owned 2,224,147 shares of the company’s stock, valued at $10,742,630.01. This represents a 12.34% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 68.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KLRS. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $34,000. Barclays PLC purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter valued at approximately $51,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics in the third quarter worth approximately $58,000. XTX Topco Ltd bought a new position in Kalaris Therapeutics in the second quarter worth approximately $65,000. Finally, WealthTrust Asset Management LLC purchased a new position in Kalaris Therapeutics during the 1st quarter worth $72,000. 66.05% of the stock is currently owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.